The benefit of minocycline on negative symptoms in schizophrenia

Not Applicable

Completed

• Conditions: Specialty: Mental Health, Primary sub-specialty: Psychosis; Mental and Behavioural Disorders

• Registration Number: ISRCTN49141214
• Lead Sponsor: Manchester Mental Health And Social Care NHS Trust

Brief Summary

2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30322824 results 2019 Results article in https://doi.org/10.3310/eme06070 NIHR journal (added 20/01/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2016-06-09
• Study Start: 2016-12-12
• Last Update Posted: 30 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

1. Male or female aged 16-35 years
2. Current DSM-IV diagnosis of schizophrenia, schizophreniform or schizoaffective psychosis, psychosis NOS as assessed with the clinical team
3. In an episode as defined by
3.1. An onset or exacerbation of symptoms
3.2. With continuing positive symptoms scoring at least mild (>2) on items P1, P2 or P6 of the PANSS within the last month
4. In contact with early intervention, community or inpatient services
5. Within 3 years of onset of symptoms
6. Current IQ greater than 70
7. Female patients must use effective birth control with a negative pregnancy test
8. Able to understand and willing to give written informed consent
9. Fluent in English

Exclusion Criteria

1. Current substance misuse diagnosis that in the opinion of the investigator may interfere with the study (urine toxicology screens will be used to monitor drug use)
2. Patients who, in the Investigator’s judgment pose a current serious suicidal or violence risk
3. Prior tetracycline use within 2 months of baseline visit or history of sensitivity or intolerance
4. History of systemic lupus erythematosis (SLE) or a history of SLE in a first-degree relative
5. Use of any investigational drug within 30 days of baseline visit
6. Relevant current or past haematologic, hepatic, renal, neurological or other medical disorder that in the opinion of the investigator may interfere with the study
7. Clinically significant deviation from the reference range in clinical laboratory test results as judged by the Investigator
8. Previous randomisation in the present study
9. Pregnant or nursing

Study & Design

• Study Type: Interventional
• Study Design: Not specified